• Globe Newswire

Global phase III trials demonstrate that nerandomilast slowed lung function decline in IPF and PPF, with similar discontinuation rates to placebo

Globenewswire -

• Globe Newswire

Boehringer provides update on iclepertin Phase III program in schizophrenia

Globenewswire -

• Globe Newswire

Philips enrolls first patient in U.S. clinical trial for innovative integrated single-device to treat peripheral artery disease

• Globe Newswire

Sabin Sends More Marburg Vaccines for Rwanda’s Outbreak

• Globe Newswire

Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients